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Summary
In 2008, the Centre Hospitalier Universitaire Vaudois
(CHUV, Lausanne, Switzerland) initiated a Fracture Li-
aison Service (FLS). All patients hospitalised for a low
trauma fracture are identified by the FLS. Inpatients then
choose to be managed by either the FLS team or their
general practitioner (GP). In this study we compared the
management between the FLS team and the GP in terms
of diagnosis of osteoporosis, treatment, refracture rates
and mortality after FLS recording. Results are compared
with the management of osteoporosis before the creation
of the FLS, as reported in the survey study Osteocare.
A total of 606 patients were included (80% women); 55%
chose management by the FLS and 45% their GP. The
mean age was 78.5, and hip was the main fracture site
(44%). The percentage of patients having dual X-ray ab-
sorptiometry to diagnose osteoporosis was significantly
higher in the FLS group than the GP group (72 vs 26.5%,
p <0.01). This percentage was 31.4% in the Osteocare
study. Overall, 50.3% of patients in the FLS group had os-
teoporosis versus 57.5% in the GP group (p <0.05). This
percentage was 46.0% in the Osteocare study.
Use of osteoporosis medication was higher in the FLS
group (FLS 100% of the patients, GP 44.1%, p <0.001)
and had increased since the Osteocare study (21.6%).
One-year nonvertebral refracture rate was higher in GP
group than in the FLS patients (5.1 vs 3.0%, p <0.05),
whereas more vertebral fractures were identified in the
FLS group, owing to protocol-driven regular clinical and
vertebral fracture assessment (VFA) evaluations (number
of evaluations 8 vs 0, p <0.01). Unadjusted mortality was
higher in GP group than in the FLS group at one and five
years (6.93 vs 2.11% and 33.58 vs. 15.96%, p <0.04). Af-
ter adjustment by age and fracture site, these results were
not significant.
With FLS management, diagnosis and treatment of osteo-
porosis were more frequent than with GP management;
new nonvertebral fractures were less frequent. Moreover,
both forms of management had increased relative to rates
reported in a 2004–2006 nationwide survey Osteocare,
before FLS creation.
Key words: osteoporosis, fracture liaison services, frac-
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Introduction
With the aging of the population and the recognised huge
economic burden of osteoporotic fractures [1–3], multidis-
ciplinary expert management of acute osteoporotic frac-
tures through what was called a Fracture Liaison Service
(FLS) was proposed. The International Osteoporosis Foun-
dation subsequently supported a “Capture the Fracture”
campaign to encourage the creation of FLS programmes
worldwide and thereby improve both the detection and
subsequent management of osteoporosis-related fractures
[4]. The two major objectives of an FLS are: (1) to reduce
the 80% of adult low-trauma fracture patients not currently
screened and/or treated for osteoporosis (“the treatment
gap”); and (2) to enhance communication between dif-
ferent healthcare providers to facilitate the treatment of
fragility fractures. Today, FLSs are widely considered the
most efficient way to identify patients with a major os-
teoporotic fracture, assess their bone status, and select the
most appropriate treatment and follow-up schedule [4].
The FLS models can be divided into four groups on the ba-
sis of the management type proposed [5]: type A is defined
as a service that identifies, investigates and initiates treat-
ment; type B is a service that identifies and investigates
patients, but refers them back to the primary care physi-
cian for treatment initiation; type C is a service that iden-
tifies patients at risk and informs them and their primary
care physician, but does not undertake any assessment or
treatment of the patients; and type D is a service that iden-
tifies patients at risk, informs and educates them but takes
no further part in others stakeholders in the patient‘s care.
Compared with the others type of FLS, type A is associ-
ated with a greater reduction in future fracture risk, more
bone health assessments and lower mortality, and is cost-
effective and cost-saving, [6].
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In 2008, an FLS was created at the Centre Hospitalier Uni-
versitaire Vaudois (CHUV), Lausanne, Switzerland. Lau-
sanne is a city of more than 133 800 people, and is the
main city of the state of Vaud, which had a population of
778 251 at the end of 2016. The CHUV is the biggest pub-
lic hospital in the canton of Vaud, and the only university
hospital. The orthopaedic capacity is 100 beds. After de-
tection by the FLS, inpatients are free to be managed by
either the FLS team or their general practitioner. Manage-
ment by the FLS team is considered to be FLS type A.
The first aim of this study was to compare osteoporosis
management (diagnosis and treatment) of patients regis-
tered with the FLS between the two forms of management
(FLS or GP). We compared these results with data record-
ed previously in the Osteocare study, before the creation
of the FLS. The second aim was to compare one- and
five-year new fracture and mortality rates between patients
managed by the FLS team and those managed by their GP.
To accomplish this, we elected to prospectively follow up
the first 1000 consecutive patients registered in the FLS.
Materials and methods
Description of the FLS at Lausanne University Hospi-
tal
The FLS first came into being at the CHUV in October
2008. Since that time, all consecutive patients hospitalised
for one or more low-trauma fractures have been registered
by a dedicated nurse (present 30% of full-time in the or-
thopaedic unit) at the time of their admission into the or-
thopaedic unit. During hospitalisation, a physician special-
ising in bone diseases meets each registered patient, apart
from patients with dementia, who are not stable, or who
refused. Depending on the patient’s estimated risk of fu-
ture osteoporotic fractures, specific management is pro-
posed; this may consist of monitoring only or monitoring
plus treatment. All baseline data are entered into a dedicat-
ed database. Patients are then allowed to choose whether
they wish to be evaluated, treated and followed up by the
FLS or by their own GP.
The standardised FLS protocol includes dual X-ray absorp-
tiometry (DXA, Hologic Inc., Bedford, MA) for assess-
ment of bone mineral density, a vertebral fracture assess-
ment (VFA), prescription of treatment and scheduling of
follow-up. Such monitoring may include: (1) a clinical and
biological evaluation 3 months after the fracture; (2) fur-
ther clinical and biological evaluations every year there-
after; and (3) follow-up with DXA plus VFA assessment
every 2 years. DXA and VFA interpretation follow the In-
ternational Society of Clinical Densitometry (ISCD) rec-
ommendations. Follow-up by the GP is not standardised.
The FLS team at CHUV evaluates roughly 600 patients
hospitalised for a fragility fracture every year.
The nationwide survey Osteocare
Between 2004 and 2006, the Osteocare Study Group per-
formed a nationwide survey of 4966 patients who present-
ed consecutively with one or more fractures at any one of
eight designated hospitals in Switzerland [7], as either an
in- or an outpatient. The CHUV participated in this study.
After data were recorded by a study nurse, an information
letter was sent to the GP about any suspected osteoporotic
fractures. Data on osteoporosis management were record-
ed on a second occasion.
Inclusion and exclusion criteria for the present study
Inclusion criteria for the current study were: being seen by
the CHUV FLS for an osteoporotic fracture; being alive at
the time of hospital discharge; and having provided written
informed consent to participate in the study. Exclusion cri-
teria were: severe dementia, an already known secondary
cause of osteoporosis, refusal to participate, and follow-up
by both their GP and the FLS team. One year after each pa-
tient’s acute fracture was registered by the FLS, data were
collected on osteoporosis management and course/events.
Patients followed up by their GP were sent a written ques-
tionnaire, and the institutional database was used to collect
information on all patients followed up by the FLS. Data
collected at 1 year of follow-up included the number and
results of DXA evaluations over the preceding year; any
osteoporosis treatment rendered (including: none; vitamin
D and/or calcium; and bone-active drugs like bisphospho-
nate, denosumab and teriparatide); any new non-traumatic
fractures; and mortality. Data on fractures at 5 years of fol-
low-up were also collected for patients followed up by the
FLS. In addition, patients who had died by 1 and 5 years
of follow-up were identified in the institutional database,
from information obtained from family members, and from
regional death records, as needed.
Statistical analysis
Differences between the two patient groups – those fol-
lowed up by the FLS and those followed up by their GP –
were identified with Student’s t-tests for continuous vari-
ables and Pearson’s chi-squared analysis for categorical
variables, and statistical significance was considered for a
two-sided test with p-value ≤0.05. All statistical analysis
were performed using Stata/IC 14.0 (StataCorp, College
Station, Texas, USA) for Windows.
Results
Characteristics of the population
The first 1000 consecutive patients were registered with
the CHUV FLS between 17 October 2008 and 27 October
2011. Figure 1 is a flow chart depicting subject recruitment
and follow-up. A total of 606 patients were included
(60.6%), 394 were excluded (139 died, 171 had a mixed
GP and FLS follow-up, and 84 refused to participate, or
had dementia or secondary osteoporosis). Overall, 55% (n
= 332) of the patients chose to be followed up by the FLS
team, and 45% (n = 274) elected to be managed by their
GP. About 80% were women in both groups. The mean age
was 78.5 years. Patients were older in GP group than in the
FLS group (79.9 vs 75.4 years, p <0.05). The proportion
of patients with hip fractures was greater in the GP group
(51.5 vs 36.5% in the FLS group, p = 0.003). In the initial
nationwide survey Osteocare, the mean age was 73.9 years
and 26.4% of the patients had a hip fracture. Baseline char-
acteristics of the 606 registered patients are summarised in
table 1. In the nationwide survey, 30.7% had an upper limb
fracture, 26.4% a lower limb fracture and 19.5% an axial
fracture [7].
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Dual X-ray absorptiometry results
The diagnostic workup for osteoporosis differed between
the groups, with 72.0% (n = 239) having DXA in FLS-
managed group and 26.5% (n = 73) in the GP-managed
group (p <0.01). In the previous nationwide survey the
percentage was 31.4%. Based on the definition of osteo-
porosis proposed by the World health Organization and
the lowest measured T-score, 50.3% in the FLS group and
57.5% in the GP group had osteoporosis (p <0.05). This
percentage was 46.0% in the nationwide survey. An addi-
tional 38% in FLS group versus 18% in the GP group had
osteopenia (p <0.05). This was 35.1% in the nationwide
survey. Normal DXA results were found in 11.7% of the
FLS group, 5.5% in the GP group (p <0.05) and 14.4% in
the nationwide survey. Nineteen percent of GP-managed
patients had no available DXA evaluation results, where-
as DXA results were available for all patients in the FLS









79.5 75.5 <0.05 73.9
% of women 81% 83%
Hip 51.5% 39.5% 0.003 26.4%
Spine 8.4% 12.7% 0.092
Pelvis 5.8% 9.6% 0.085
Humerus 12.4% 11.5% 0.617
Radius 5.5% 7.5% 0.310
Others 16.4% 19.3% 0.303
FLS = Fracture Liaison Service; GP = general practitioner
group (table 2). In the nationwide survey, 4.5% of the sub-
jects lacked DXA results.
Osteoporosis treatment
The percentage of patients receiving a prescription for
some osteoporosis-specific therapy (i.e., a bone-active
drug) was 79.0% in the FLS group and 38.8% in the GP
group (p <0.001). Only 21.6% of the patients had a bone-
active drug prescribed in the nationwide survey. In all
groups, the majority of patients were prescribed a bisphos-
phonate (table 3).
New fractures
Data on incident fractures were available for 100% (n =
332) and 78% (n = 214) of patients in the FLS and GP
groups, respectively; 15.1% had a second low-trauma frac-








Yes 26.5% 72.0%* 31.4%
No 45.5%* 28.0%
Unknown 28.0% 0.0%
DXA normal 5.5% 11.7%* 14.4%
DXA osteopenia 18.0% 38.0%* 35.1%
DXA osteoporosis 57.5% 50.3%* 46.0%
Result not known 19.0% 0.0%* 4.5%
DXA = dual X-ray absorptiometry results; FLS = Fracture Liaison Ser-
vice; GP = general practitioner * p <0.05
Figure 1: Study flowchart.
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ture. The most commonly affected site was the hip. At
1 year, a new fracture had occurred in 5.4% and 5.1%
of patients managed by the FLS and the GP, respectively
(p = 0.80). A vertebral fracture was documented in eight
patients at 1 year, all in the FLS group; this included
one patient with three clinical vertebral fractures, and sev-
en patients with one to three new asymptomatic fractures
detected by VFA. After exclusion of vertebral fractures,
which were screened for systematically by the FLS team
but not by GPs, at least one new nonvertebral fracture was
documented in 3.0% of patients in the FLS group and 5.1%
in the GP group (p <0.05) (table 4). The proportions of pa-
tients with a new fracture who were given an osteoporosis-
specific treatment (a bisphosphonate, denosumab, or teri-
paratide) were the same in both groups. After between 1
and 5 years of follow-up, data were available only for the
FLS patients, among whom 40 had a new fracture, includ-
ing vertebral fractures (12.3%).
Mortality
Over the first year after registration with the FLS, 7 pa-
tients followed up by the FLS team died compared with
19 followed up by their GP (2.1 vs 6.9%, p = 0.04). The
mean times to death were 0.68 years (range 0.36–0.85) and
0.50 years (range 0.07–0.96), respectively (p = 0.05). Over
a mean follow-up period of 5.62 years (range 3.84–6.86),
145 of the 606 patients died (24%): 53/332 in the FLS
group and 92/274 in the GP group (16.0 vs 33.6%, p =
0.001). When adjusted for age and fracture site, these dif-
ferences were not statistically significant (table 5).
Discussion
The key results of our study showed that the diagnosis and
treatment of osteoporosis is more frequent for patients fol-
lowed by the FLS team than for those followed by their
GP after their acute low trauma fracture and both of them
Table 3: Treatment proposed after the fracture
GP group FLS group




Type of treatment (n = 103) (n = 332)
Calcium and/or vitamin D alone 63 (61.2%) 70 (21.0%)
Zoledronate 16 (15.6%) 141 (42.5%)
Alendronate 2 (1.9%) 51 (15.3%)
Ibandronate IV 16 (15.6%) 33 (10.0%)
Risedronate 3 (2.9%) 3 (0.9%)
Teriparatide 2 (1.9%) 20 (6.0%)
Denosumab 1 (0.9%) 13 (4.0%)
Pamidronate 0 1 (0.3%)
FLS = Fracture Liaison Service; GP = general practitioner






New fracture (with VF) 5.1% 5.4% 0.80
New fracture (without VF) 5.1% 3.0% <0.05
FLS = Fracture Liaison Service; GP = general practitioner; VF = verte-
bral fracture
have increased relative to rates reported before the FLS
creation. Relative to the GP management patients, FLS fol-
lowed patients had fewer nonvertebral refractures and a de-
creased risk of death. These results are important in a coun-
try where the incidence of osteoporotic fractures is high [8]
and where osteoporosis is associated with an increase mor-
bidity and mortality [9, 10].
Although effective treatments for osteoporosis are current-
ly available, the “treatment gap” between patients who
should receive a bone-active drug and those who are effec-
tively treated is increasing worldwide, with more than 50%
of women and 36% of men undertreated in Switzerland
[11, 12]. Patients at high risk for fragility fractures should
be treated, especially after an osteoporotic fracture has oc-
curred. Fracture liaison services are the most efficient way
to enhance osteoporotic fracture detection.
Compared with the results of the nationwide survey, since
the FLS implementation a higher proportion of patients
had a DXA evaluation and the prescription of an active os-
teoporosis-specific treatment. These increases were greater
in patients managed by the FLS team than in those man-
aged by their GP. In fact, among patients managed by
their GP, only the proportion receiving osteoporosis-spe-
cific therapy increased compared with the nationwide sur-
vey, and not the percentage having DXA,. These results are
consistent with other publications. FLS type A versus GP
has been shown to more effectively increase the number
of DXA evaluations from 6% to a maximum of 85%, de-
pending on the site of the fracture and the study [13–18]. In
our study, even after a low-trauma fracture, only 50 to 53%
of patients were in the osteoporotic range, with more than
50% having either osteopenia or a normal result, which is
consistent with others’ data [13, 17, 19, 20]. Osteoporot-
ic fracture risk is not well detected by the measurement of
bone mineral density alone.
The frequency of prescription of an active osteoporotic
drug increased and reached 79% in the FLS, but remained
low in the GP group (39%). Our results are comparable to
other publications, confirming the more appropriate care
by a type A FLS [13, 15, 16, 21, 22]. The remaining diffi-
culty is adherence to the treatment, which seems to be bet-
ter with intravenous, bisphosphonates. Indeed, adherence
to osteoporosis medication is well known to decline with
time, but seems to be better with an annual intravenous in-
fusion. In our study, we did not record adherence to oral
medication, but most patients received intravenous med-
ication (52.5% in the FLS group, 31.2% in the GP group)
[6].
In our study, a significantly higher proportion of patients
had new nonvertebral fragility fractures in the GP group
compared with patients treated and followed by the FLS.
These results are comparable to other studies [21, 23] and
are relevant, since “less intense” FLS models have not
demonstrated any improvement on refracture rates [6].








After 1 year 6.9% 2.1% 0.04 NS
After 5.62
years
33.6% 16.0% 0.001 NS
FLS = Fracture Liaison Service; GP = general practitioner; NS = not
significant * p-value adjusted for age and hip fracture.
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However, data about vertebral fractures are not known and,
among published studies evaluating the rate of new frac-
tures after FLS implementation, the majority excluded ver-
tebral fractures [23, 24]. We documented eight vertebral
fractures in the FLS group (seven of which were asympto-
matic) versus none in the GP group in the first year. This
reflects the routine DXA and VFA evaluations performed
in the FLS group (not or rarely performed by the GPs)
rather than any true inter-group difference in fracture inci-
dence and highlights the persistent challenge of the diag-
nosis of vertebral fractures: more than 50% are misdiag-
nosed [25–28], even in a FLS [28, 29]. Education, teaching
[30], and implementation of systematic VFA in addition to
DXA could decrease this level of misdiagnosis. Neverthe-
less, even if the VFA has a high specificity, the sensitivity
remains low, and osteoporotic patients with new back pain
should have a spinal X-Ray in order to confirm a new ver-
tebral fracture [31]. This diagnosis reflects the severity of
the disease and has an impact on the choice of the treat-
ment.
In terms of death, we failed to identify any statistically sig-
nificant difference between the FLS and GP groups, after
adjusting for age and previous fracture site. However, these
results might be biased for several reasons. For example,
since the CHUV is a university-based hospital, it is rea-
sonable to expect that patients with more comorbid con-
ditions would be more likely to choose follow-up by the
FLS team. Since we did not collect data on comorbid con-
ditions, we cannot rule this possibility out. Few FLS stud-
ies have used mortality as an outcome. However, some of
them have described a 20 to 35% decrease in mortality [23,
32].
Our study has limitations. First, for patients followed by
their GP, data were collected by asking patients (or family
members) to complete a questionnaire. It appeared clear
that most of these patients were not well informed about
their management. For example, 28% of patients did not
know if they had undergone a DXA evaluation, 19% of
those having DXA did not know the results and 23.4% did
not know if they had received osteoporosis-specific med-
ication. It is well known that reduced familiarity with treat-
ment decreases adherence [33–36]. This point underlines
the importance of increasing patients’ education through
the FLS and through GP education. A second limitation
pertains to patient age and the sites of fracture. Older pa-
tients were more likely to have hip fractures and to be fol-
lowed up by their GP, as already observed in other studies
[21, 22]. As such, we failed to observe any significant de-
crease in the 1-year rate of death in the FLS group relative
to patients followed up by their GP when the analysis was
adjusted for age and fracture site.
These limitations aside, several finding are worthy of no-
tice. First, the management of osteoporosis in our hospi-
tal’s catchment area improved from 2004–2006 (date of the
nationwide survey) to 2011. All results were highly signif-
icant when the patient was managed by our type A FLS,
and prescription of specific treatment increased when the
patient decided to be followed up by the GP. We had pre-
viously informed local GPs about the results of the nation-
wide survey, and about our reasons for establishing a frac-
ture liaison service type A at our hospital. We informed
them when we started the CHUV FLS. Potentially, either
or both of these actions had some positive impact upon
their osteoporosis management. These results are in accor-
dance with the literature and could by be easily general-
isable in the others osteoporosis centres through Switzer-
land.
In conclusion, our study adds further support to the fact
that fracture liaison services enhance the detection and
subsequent management of patients with a major osteo-
porotic fracture. Such services may also reduce the inci-
dence of future fractures. Detection of vertebral fractures
remains low, and an FLS dedicated to spine management
(FLS spine) are currently in development.
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